口服维生素A预防儿童及年轻成人移植物抗宿主病的随机2期试验
这项前瞻性随机双盲安慰剂对照2期试验将80例造血干细胞移植受者按1:1随机分组,移植前接受单次口服大剂量维生素A(4000 IU/kg,最大250 000 IU)或安慰剂。意向治疗分析中,维生素A组与安慰剂组急性GVHD发生率分别为12.5%和20%(P=0.5),1年慢性GVHD发生率分别为5%和15%(P=0.02)。作者认为移植前口服维生素A价格低廉、毒性低,可减少GVHD。
要点
- 移植前单次口服维生素A 4000 IU/kg(最大250 000 IU)未显著降低第+100天急性GVHD发生率(12.5% vs 20%,P=0.5)。
- 1年慢性GVHD发生率维生素A组5% vs 安慰剂组15%(P=0.02)。
- 唯一可能相关毒性为1例维生素A组受者在第+30天出现无症状3级高胆红素血症,自行缓解。
核心结论
- 移植前口服维生素A价格低廉、毒性低,并可减少GVHD。
研究设计与样本
- 前瞻性随机双盲安慰剂对照2期临床试验,80例造血干细胞移植受者按1:1随机接受移植前大剂量维生素A或安慰剂。
- 维生素A为单次口服4000 IU/kg,最大250 000 IU,于预处理前给药。
- 主要终点为第+100天急性GVHD发生率。
主要发现
- 意向治疗分析中,第+100天急性GVHD发生率维生素A组12.5% vs 安慰剂组20%(P=0.5)。
- 第+180天急性胃肠道GVHD发生率维生素A组2.5% vs 安慰剂组12.5%(P=0.09)。
- 1年慢性GVHD发生率维生素A组5% vs 安慰剂组15%(P=0.02)。
- 按实际治疗分析中,第+180天急性胃肠道GVHD累积发生率维生素A组0% vs 安慰剂组12.5%(P=0.02),慢性GVHD累积发生率维生素A组2.7% vs 安慰剂组15%(P=0.01)。
- 移植后第+30天,反映肠道T细胞迁移的绝对CCR9+ CD8+效应记忆T细胞在维生素A组较低(P=0.01);维生素A组血清淀粉样蛋白A-1、白细胞介素-6、白细胞介素-8及肿瘤抑制因子2水平较低,并可能具有更有利的肠道微生物组与短链脂肪酸。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vitamin A plays a key role in the maintenance of gastrointestinal homeostasis and promotes a tolerogenic phenotype in tissue resident macrophages. We conducted a prospective randomized double-blinded placebo-controlled clinical trial in which 80 recipients of hematopoietic stem cell transplantation (HSCT) were randomized 1:1 to receive pretransplant high-dose vitamin A or placebo. A single oral dose of vitamin A of 4000 IU/kg, maximum 250 000 IU was given before conditioning. The primary end point was incidence of acute graft-versus-host disease (GVHD) at day +100. In an intent-to-treat analysis, incidence of acute GVHD was 12.5% in the vitamin A arm and 20% in the placebo arm (P = .5). Incidence of acute gastrointestinal (GI) GVHD was 2.5% in the vitamin A arm (P = .09) and 12.5% in the placebo arm at day +180. Incidence of chronic GVHD was 5% in the vitamin A arm and 15% in the placebo arm (P = .02) at 1 year. In an "as treated" analysis, cumulative incidence of acute GI GVHD at day +180 was 0% and 12.5% in recipients of vitamin A and placebo, respectively (P = .02), and cumulative incidence of chronic GVHD was 2.7% and 15% in recipients of vitamin A and placebo, respectively (P = .01). The only possibly attributable toxicity was asymptomatic grade 3 hyperbilirubinemia in 1 recipient of vitamin A at day +30, which self-resolved. Absolute CCR9+ CD8+ effector memory T cells, reflecting gut T-cell trafficking, were lower in the vitamin A arm at day +30 after HSCT (P = .01). Levels of serum amyloid A-1, a vitamin A transport protein with proinflammatory effects, were lower in the vitamin A arm. The vitamin A arm had lower interleukin-6 (IL-6), IL-8, and suppressor of tumorigenicity 2 levels and likely a more favorable gut microbiome and short chain fatty acids. Pre-HSCT oral vitamin A is inexpensive, has low toxicity, and reduces GVHD. This trial was registered at www.ClinicalTrials.gov as NCT03202849.
引用
- Khandelwal P, Langenberg L, Luebbering N, et al. A randomized phase 2 trial of oral vitamin A for graft-versus-host disease in children and young adults. Blood. 2024. PMID: 38227933. doi:10.1182/blood.2023022865
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。